Amgen Inc Patent Portfolio Statistics

Amgen Inc

Amgen Inc`s Profile

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of Amgen Inc look like?

Total Applications:	51
Granted Patents:	37
Grant Index	80.43 %
Abandoned/Rejected Applications:	9 (19.57%)
In-Process Applications:	5
Average Grant Time:	3.41 Years
Average Office Actions:	2.14

Which Technology Area Amgen Inc is filing most patents in? (Last 10 years)

Art Unit	Definition	Total Applications
1647	Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology	11
3783	Body Treatment, Kinestherapy, and Exercising	10
1643	Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology	5
1649	Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology	5
1636	Molecular Biology, Bioinformatics, Nucleic Acids, Recombinant DNA and RNA, Gene Regulation, Nucleic Acid Amplification, Animals and Plants, Combinatorial/ Computational Chemistry	3

How many patents are Amgen Inc filing every year?

Year	Total Applications
2022	0*
2021	0*
2020	0
2019	6
2018	9

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of Amgen Inc in USPTO?

Publication number: US20220026442A1

Abstract:
The invention provides a method for controlling contaminants in biopharmaceutical purification processes by using light scattering and UV absorbance to establish a determinant. The invention makes use of multi-angle light scattering (MALS) and UV as a continuous monitoring system to provide information about the elution peak fractions in real-time instead of conventional pooling methods that rely on a predetermined percent UV peak max value to initiate the pooling process; regardless of product quality.

Publication date: 2022-01-27
Applicant: Amgen Inc
Inventors: Duke H Phan

Publication number: –

Abstract:
None

Publication date: –
Applicant: Amgen Inc
Inventors: Jimmie L Ward

Publication number: US20220017584A1

Abstract:
GDF15 molecules are provided herein. In some embodiments, the GDF15 molecule is a GDF15-Fc fusion, in which a GDF15 region is fused to an Fc region. In some embodiments, the GDF15 region is fused to the Fc region via a linker. Also, provided herein are methods for making and using GDF15 molecules.

Publication date: 2022-01-20
Applicant: Amgen Inc
Inventors: Ellison Marie Murielle Veniant

How are Amgen Inc’s applications performing in USPTO?

Application Number	Title	Status	Art Unit	Examiner
17495963	Method For Using Light Scattering In Real Time To Directly Monitor And Control Impurity Removal In Purification Processes	–	1644	Rogers, James L
17602148	Drug Delivery Device With Smart Grip	Application Undergoing Preexam Processing	–	–
17494001	Growth Differentiation Factor 15 Fusion Proteins	–	1646	–
17482230	Kras G12C Inhibitors And Methods Of Using The Same	Application Undergoing Preexam Processing	1625	–
17435768	Use Of Oncolytic Viruses For The Treatment Of Cancer	Docketed New Case – Ready for Examination	OPAP	Central, Docket